253 related articles for article (PubMed ID: 30150374)
1. Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice.
Wang Y; Su L; Morin MD; Jones BT; Mifune Y; Shi H; Wang KW; Zhan X; Liu A; Wang J; Li X; Tang M; Ludwig S; Hildebrand S; Zhou K; Siegwart DJ; Moresco EMY; Zhang H; Boger DL; Beutler B
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8698-E8706. PubMed ID: 30150374
[TBL] [Abstract][Full Text] [Related]
2. Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.
Morin MD; Wang Y; Jones BT; Mifune Y; Su L; Shi H; Moresco EMY; Zhang H; Beutler B; Boger DL
J Am Chem Soc; 2018 Oct; 140(43):14440-14454. PubMed ID: 30272974
[TBL] [Abstract][Full Text] [Related]
3. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
4. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim.
Su L; Wang Y; Wang J; Mifune Y; Morin MD; Jones BT; Moresco EMY; Boger DL; Beutler B; Zhang H
J Med Chem; 2019 Mar; 62(6):2938-2949. PubMed ID: 30829478
[TBL] [Abstract][Full Text] [Related]
6. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
7. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Ye L; Xing Y; Hu J; Xi T
Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
[TBL] [Abstract][Full Text] [Related]
8. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
Joseph AM; Srivastava R; Zabaleta J; Davila E
Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
[TBL] [Abstract][Full Text] [Related]
11. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.
Santone M; Aprea S; Wu TY; Cooke MP; Mbow ML; Valiante NM; Rush JS; Dougan S; Avalos A; Ploegh H; De Gregorio E; Buonsanti C; D'Oro U
Hum Vaccin Immunother; 2015; 11(8):2038-50. PubMed ID: 26024409
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
[TBL] [Abstract][Full Text] [Related]
13. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.
Asprodites N; Zheng L; Geng D; Velasco-Gonzalez C; Sanchez-Perez L; Davila E
FASEB J; 2008 Oct; 22(10):3628-37. PubMed ID: 18587008
[TBL] [Abstract][Full Text] [Related]
14. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response.
Yang MH; Russell JL; Mifune Y; Wang Y; Shi H; Moresco EMY; Siegwart DJ; Beutler B; Boger DL
J Med Chem; 2022 Jul; 65(13):9230-9252. PubMed ID: 35767437
[TBL] [Abstract][Full Text] [Related]
16. An Immunomodulatory Gallotanin-Rich Fraction From
Lasso P; Gomez-Cadena A; Urueña C; Donda A; Martinez-Usatorre A; Romero P; Barreto A; Fiorentino S
Front Immunol; 2020; 11():584959. PubMed ID: 33312174
[TBL] [Abstract][Full Text] [Related]
17. Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation.
Zhang W; Okimura T; Xu L; Zhang L; Oda T; Kwak M; Yu Q; Jin JO
Oncotarget; 2016 Apr; 7(15):19284-98. PubMed ID: 27008707
[TBL] [Abstract][Full Text] [Related]
18. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
19. Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response.
Wijayadikusumah AR; Zeng W; McQuilten HA; Wong CY; Jackson DC; Chua BY
Mol Pharm; 2019 May; 16(5):2037-2047. PubMed ID: 30924661
[TBL] [Abstract][Full Text] [Related]
20. Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α.
Hartley G; Regan D; Guth A; Dow S
Cancer Immunol Immunother; 2017 Apr; 66(4):523-535. PubMed ID: 28184968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]